

# Tomasz StompÅ³r

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4284083/publications.pdf>

Version: 2024-02-01

85  
papers

1,220  
citations

430874

18  
h-index

414414

32  
g-index

87  
all docs

87  
docs citations

87  
times ranked

1519  
citing authors

#	ARTICLE	IF	CITATIONS
1	An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 2003, 41, 203-211.	1.9	154
2	The pharmacokinetics of pioglitazone in patients with impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 368-374.	2.4	125
3	Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 917-924.	0.7	66
4	Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10822.	4.1	66
5	Prevalence of Chronic Pain, Particularly with Neuropathic Component, and Its Effect on Overall Functioning of Elderly Patients. <i>Medical Science Monitor</i> , 2019, 25, 2695-2701.	1.1	51
6	Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 404-412.	0.7	39
7	An Overview of the Pathophysiology of Vascular Calcification in Chronic Kidney Disease. <i>Peritoneal Dialysis International</i> , 2007, 27, 215-222.	2.3	39
8	Selected Growth Factors in Peritoneal Dialysis: Their Relationship to Markers of Inflammation, Dialysis Adequacy, Residual Renal Function, and Peritoneal Membrane Transport. <i>Peritoneal Dialysis International</i> , 2002, 22, 670-676.	2.3	35
9	Coronary artery calcification in chronic kidney disease: An update. <i>World Journal of Cardiology</i> , 2014, 6, 115.	1.5	35
10	An Association between Aortic Pulse Wave Velocity, Blood Pressure and Chronic Inflammation in ESRD Patients on Peritoneal Dialysis. <i>International Journal of Artificial Organs</i> , 2003, 26, 188-195.	1.4	30
11	Coronary Artery Calcification, Common Carotid Artery Intima-Media Thickness and Aortic Pulse Wave Velocity in Patients on Peritoneal Dialysis. <i>International Journal of Artificial Organs</i> , 2006, 29, 736-744.	1.4	28
12	Clinicopathologic correlations of renal pathology in the adult population of Poland. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, ii209-ii218.	0.7	28
13	Prevalence and prediction of renal artery stenosis in patients with coronary and supraaortic artery atherosclerotic disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 580-585.	0.7	27
14	Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland. <i>BMC Nephrology</i> , 2016, 17, 194.	1.8	26
15	Endothelial progenitor cells participation in cardiovascular and kidney diseases: a systematic review. <i>Acta Biochimica Polonica</i> , 2016, 63, 475-82.	0.5	24
16	Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2323-2327.	0.7	23
17	Association between Gastric Emptying Rate and Nutritional Status in Patients Treated with Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2002, 22, 500-505.	2.3	22
18	Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease – Position Statement of the Working Group of the Polish Society of Nephrology. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 959-969.	2.0	22

#	ARTICLE	IF	CITATIONS
19	Selenium status indices, laboratory data, and selected biochemical parameters in end-stage renal disease patients. <i>Biological Trace Element Research</i> , 2007, 116, 29-41.	3.5	19
20	The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 522-527.	1.0	17
21	An overview of the pathophysiology of vascular calcification in chronic kidney disease. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S215-22.	2.3	17
22	An Association between Body Mass Index and Markers of Inflammation: Is Obesity the Proinflammatory State in Patients on Peritoneal Dialysis?. <i>Peritoneal Dialysis International</i> , 2003, 23, 79-83.	2.3	16
23	Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization. <i>Toxins</i> , 2021, 13, 274.	3.4	14
24	Hypertensive kidney disease: true epidemic or rare disease?. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 130-139.	0.4	14
25	LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 59v-62.	0.7	13
26	Long-Term Cholecalciferol Administration in Hemodialysis Patients: A Single-Center Randomized Pilot Study. <i>Medical Science Monitor</i> , 2014, 20, 2228-2234.	1.1	13
27	Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. <i>Peritoneal Dialysis International</i> , 2002, 22, 670-6.	2.3	13
28	Trends in coronary artery calcification in peritoneal dialysis and transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3205-3206.	0.7	12
29	WNT4 Expression in Primary and Secondary Kidney Diseases: Dependence on Staging. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 200-210.	2.0	12
30	Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-10.	4.0	12
31	FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. <i>Frontiers in Immunology</i> , 2021, 12, 720183.	4.8	12
32	Renal Transplantation Ameliorates the Progression of Arterial Stiffness in Patients Treated with Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2005, 25, 492-496.	2.3	11
33	Identification of Inflamed Atherosclerotic Plaque using <sup>123</sup> I-Labeled Interleukin-2 Scintigraphy in High-Risk Peritoneal Dialysis Patients: A Pilot Study. <i>Peritoneal Dialysis International</i> , 2009, 29, 568-574.	2.3	11
34	C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 247.	2.7	10
35	An association between body mass index and markers of inflammation: is obesity the proinflammatory state in patients on peritoneal dialysis?. <i>Peritoneal Dialysis International</i> , 2003, 23, 79-83.	2.3	10
36	Renal transplantation ameliorates the progression of arterial stiffness in patients treated with peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2005, 25, 492-6.	2.3	10

#	ARTICLE	IF	CITATIONS
37	Blood pressure and arterial stiffness in patients with high sodium intake in relation to sodium handling and left ventricular diastolic dysfunction status. <i>Journal of Human Hypertension</i> , 2015, 29, 583-591.	2.2	9
38	Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 225-234.	2.9	9
39	Imaging of inflamed carotid artery atherosclerotic plaques with the use of <sup>99m</sup> Tc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 673-682.	6.4	7
40	Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease. <i>Nutrients</i> , 2021, 13, 789.	4.1	7
41	Osteoporosis in mineral and bone disorders of chronic kidney disease. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 314-320.	0.4	7
42	Renal involvement in multiple myeloma. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 443-448.	0.4	7
43	Renal involvement in multiple myeloma. , 2012, 122, 443-8.		7
44	Trends and Dynamics of Changes in Aortic Pulse Wave Velocity over One-year Observation Period in Patients Treated with Peritoneal Dialysis. <i>International Journal of Artificial Organs</i> , 2004, 27, 904-906.	1.4	6
45	Pulse wave velocity and proteins regulating vascular calcification and bone mineralization in patients treated with peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3605-3606.	0.7	6
46	Gout, hyperuricemia and chronic kidney disease: New treatment possibilities. <i>Polish Annals of Medicine</i> , 2016, 23, 195-201.	0.3	6
47	Can we prolong life of patients with advanced chronic kidney disease: what is the clinical evidence?. <i>Polish Archives of Internal Medicine</i> , 2013, 121, 88-93.	0.4	6
48	Association between gastric emptying rate and nutritional status in patients treated with continuous ambulatory peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2002, 22, 500-5.	2.3	6
49	SARS-CoV-2 mRNA Vaccine-Induced Cellular and Humoral Immunity in Hemodialysis Patients. <i>Biomedicines</i> , 2022, 10, 636.	3.2	6
50	Understanding the variability in Ultrafiltration Obtained with Icodextrin. <i>Peritoneal Dialysis International</i> , 2009, 29, 407-411.	2.3	5
51	Unusual manifestation of crystalline light chain tubulopathy in patient with multiple myeloma: case report and review of the literature. <i>Renal Failure</i> , 2014, 36, 795-799.	2.1	5
52	Dialysis adequacy, residual renal function and serum concentrations of selected low molecular weight proteins in patients undergoing continuous ambulatory peritoneal dialysis. <i>Medical Science Monitor</i> , 2003, 9, CR500-4.	1.1	5
53	Elevated levels of N <sup>ε</sup> -homocysteinyl-lysine isopeptide in patients on long-term hemodialysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1373-8.	2.3	4
54	Versatility of USP18 in physiology and pathophysiology. <i>Acta Biochimica Polonica</i> , 2019, 66, 389-392.	0.5	4

#	ARTICLE	IF	CITATIONS
55	Renoprotective effects of benazepril: current perspective. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 663-673.	1.5	3
56	The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 186.	2.5	3
57	Renalase in chronic kidney disease: the evolving story. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 89-90.	0.4	3
58	Acute myocarditis with heart failure in the course of eosinophilic granulomatosis with polyangiitis in a patient on maintenance hemodialysis. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 202-203.	0.4	3
59	What do we know about biomarkers in diabetic kidney disease?. <i>Endokrynologia Polska</i> , 2020, 71, 545-550.	1.0	3
60	Heparin-induced thrombocytopenia as a cause of prolonged low platelet count in patient with thrombotic thrombocytopenic purpura treated with plasmapheresis. <i>Acta Biochimica Polonica</i> , 2017, 64, 375-376.	0.5	2
61	Pure Red Cell Aplasia and Antibody-Mediated Rejection: Double Trouble in 1 Kidney Transplant Recipient Solved by Intravenous Immunoglobulin Infusion: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2530-2532.	0.6	2
62	Why albuminuria should be assessed more frequently in everyday clinical practice? Position statement. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 396-406.	0.4	2
63	Diagnosis and treatment of type 2 diabetes mellitus in patients with chronic kidney disease and eGFR < 60 mL/min <sup>2</sup> a position statement of the Polish Society of Nephrology Working Group on Metabolic and Endocrine Disorders in Kidney Diseases. <i>Endokrynologia Polska</i> , 2020, 71, 3-14.	1.0	2
64	Identifying chronic kidney disease in an emergency department: a chance for an early diagnosis. <i>Polish Archives of Internal Medicine</i> , 2011, 121, 23-28.	0.4	2
65	Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study. <i>Medical Science Monitor</i> , 2020, 26, e921919.	1.1	2
66	Antibodies against N <sup>ε</sup> -homocysteinylated proteins in patients on different methods of renal replacement therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1093-9.	2.3	1
67	Tamoxifen as the possible cause of severe thromboembolic complications in a patient with a history of renal transplantation and encapsulating peritoneal sclerosis. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 259-261.	0.4	1
68	Endogenous lithium clearance: a diagnostic method of assessing sodium sensitivity in hypertension. Methodological and clinical implications. <i>Kardiologia Polska</i> , 2014, 72, 1-7.	0.6	1
69	ZespÅ <sup>3</sup> Å, metaboliczny wÅ <sup>3</sup> rÅ <sup>3</sup> d mÅ <sup>3</sup> Å <sup>3</sup> 4czyn z wojewÅ <sup>3</sup> dzstwa warmiÅ <sup>3</sup> ,sko-mazurskiego w Polsce. <i>Arterial Hypertension</i> , 2017, 21, 148-152.	0.3	1
70	Can we prolong life of patients with advanced chronic kidney disease: what is the clinical evidence?. , 2011, 121, 88-93.		1
71	The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease. <i>Vascular Disease Prevention</i> , 2006, 3, 165-172.	0.2	0
72	Advanced abdominal arterial calcification sparing kidney allograftâ€”case report. <i>Renal Failure</i> , 2013, 35, 1031-1034.	2.1	0

#	ARTICLE	IF	CITATIONS
73	Chronic kidney disease in elderly â€“ Fact or fiction?. Polish Annals of Medicine, 2014, 21, 90-95.	0.3	0
74	Kidney and heart: TGFÎ²1-mediated cross-talk. Kardiologia Polska, 2013, 71, 129-129.	0.6	0
75	Dual blockade of the reninâ€“angiotensinâ€“aldosterone system in renal disease: what is the future?. Polish Archives of Internal Medicine, 2014, 124, 72-73.	0.4	0
76	High rate of aspirin resistance in advanced kidney failure: does it matter?. Kardiologia Polska, 2014, 72, 401-402.	0.6	0
77	Folic acid improves renal function â€” in what mechanism?. Kardiologia Polska, 2015, 73, 469-469.	0.6	0
78	Vitamin K in chronic kidney disease: time for a (hint of) hope?. Polish Archives of Internal Medicine, 2015, 125, 618-619.	0.4	0
79	Abandonment of internal medicine as a specialty: the point of no return?. Polish Archives of Internal Medicine, 2016, 126, 824-826.	0.4	0
80	AktywnoÅ› fizyczna, nadciÅ›nienie tÅ™tnicze i obwÃ³d pasa u mÃ³Å¼czyzn z wojewÃ³dztwa warmiÃ„sko-mazurskiego w Polsce. Arterial Hypertension, 2017, 21, 140-147.	0.3	0
81	Wyzwania wczesnej diagnostyki szpiczaka plazmocytoowego â€“ algorytm diagnostyczny. Acta Haematologica Polonica, 2019, 50, 121-129.	0.3	0
82	Recurrent lower urinary tract infections in adults: donâ€™t think it is E. coli, donâ€™t choose ciprofloxacin to treat. Polish Archives of Internal Medicine, 2020, 130, 369-370.	0.4	0
83	Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. Cardiology Journal, 2021, , .	1.2	0
84	What is the prognostic value of reduced eGFR?. Polski Merkurusz Lekarski, 2021, 49, 13-18.	0.3	0
85	Serum WNT4 protein as an indicator of chronic glomerulonephritis but not a marker of inflammatory cell infiltration and fibrosis: A preliminary study. Advances in Clinical and Experimental Medicine, 2022, 31, 249-259.	1.4	0